RP
DGX icon

Riverwater Partners’s Quest Diagnostics DGX Stock Holding History

Riverwater Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.11M Buy
20,973
+5,232
+33% +$1.02M 1.37% 11
2025
Q4 		$2.73M Buy
15,741
+2,160
+16% +$393K 1.06% 21
2025
Q3 		$2.59M Buy
13,581
+399
+3% +$70.8K 1.07% 23
2025
Q2 		$2.37M Sell
13,182
-31
-0.2% -$5.38K 1.12% 21
2025
Q1 		$2.24M Buy
13,213
+2,855
+28% +$469K 1.15% 20
2024
Q4 		$1.56M Buy
10,358
+152
+1% +$23.6K 0.76% 37
2024
Q3 		$1.58M Buy
10,206
+27
+0.3% +$4.03K 0.78% 36
2024
Q2 		$1.39M Sell
10,179
-56
-0.5% -$7.67K 1.03% 20
2024
Q1 		$1.36M Buy
10,235
+3,559
+53% +$462K 1% 21
2023
Q4 		$921K Buy
6,676
+45
+0.7% +$5.92K 0.73% 33
2023
Q3 		$808K Buy
6,631
+2,114
+47% +$282K 0.73% 34
2023
Q2 		$635K Buy
4,517
+204
+5% +$28.1K 0.56% 53
2023
Q1 		$610K Buy
4,313
+63
+1% +$9.01K 0.56% 53
2022
Q4 		$665K Buy
4,250
+194
+5% +$27.9K 0.57% 54
2022
Q3 		$498K Hold
4,056
– – 0.5% 63
2022
Q2 		$539K Buy
4,056
+284
+8% +$38.7K 0.54% 55
2022
Q1 		$516K Sell
3,772
-1,948
-34% -$272K 0.85% 53
2021
Q4 		$990K Buy
+5,720
New +$870K 0.88% 27

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Riverwater Partners's DGX Position: Q1 2026 in Review

Riverwater Partners increased its Quest Diagnostics (DGX) stake by 33% in Q1 2026, buying an estimated $1.02M and bringing the position to 20,973 shares worth $4.11M. The position accounts for 1.37% of the portfolio, ranked #11.

Riverwater Partners first reported a position in DGX in Q4 2021 and has held it in 18 quarters since. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Riverwater Partners held 20,973 shares of Quest Diagnostics worth $4.11M as of Q1 2026.
  • Riverwater Partners bought 5,232 Quest Diagnostics shares in Q1 2026, an estimated $1.02M.
  • Quest Diagnostics made up 1.37% of Riverwater Partners's portfolio in Q1 2026, its #11 holding.
  • Riverwater Partners first reported a position in Quest Diagnostics in Q4 2021 and has held it in 18 quarters since.
  • 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Riverwater Partners's 13F filing for Q1 2026, filed 8 May 2026.